Sandoz Launches Enzeevu Biosimilar In US For Retinal Diseases
Nov 16 (Reuters) - SANDOZ GROUP AG SDZ.S:
SANDOZ LAUNCHES ENZEEVU IN THE US AND ANNOUNCES KEY PRIVATE LABEL AGREEMENT, EXPANDING TREATMENT CHOICE FOR PATIENTS WITH RETINAL DISEASES
TARGETS OVER 100 BIOSIMILARS IN PORTFOLIO BY 2040
ENZEEVU LAUNCH TARGETS US ANTI-VEGF MARKET ESTIMATED AT $9.60 BILLION
TO MANUFACTURE ENZEEVU FOR PRIVATE LABEL BEGINNING MID-2027
LAUNCHES ENZEEVU (AFLIBERCEPT-ABZV) 2 MG IN US
Further company coverage: SDZ.S